Antiviral therapy in compensated and decompensated cirrhotic patients with chronic HCV infection

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 12, 2009, Pages 1929-1938

  Iacobellis, Angelo ^a   Andriulli, Angelo ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

Antiviral therapy; Cirrhosis; HCV infection; Peginterferon; Ribavirin

Indexed keywords

ANTIANEMIC AGENT; ELTROMBOPAG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RIBAVIRIN;

ABDOMINAL PAIN; ANEMIA; ANTIVIRAL THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DECOMPENSATED LIVER CIRRHOSIS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; HEADACHE; HEPATITIS C; HUMAN; INFECTION; LIVER BIOPSY; LIVER TRANSPLANTATION; LOW DRUG DOSE; MORBIDITY; MORTALITY; NAUSEA; NAUSEA AND VOMITING; NEUTROPENIA; REVIEW; THROMBOCYTOPENIA; XEROSTOMIA;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 68149178482     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903066811     Document Type: Review

References (64)

1. Omata M, Shiratori Y. Long-term effects of interferon therapy on histology and development of hepatocellular carcinoma in hepatitis C. J Gastroenterol Hepatol 2000;15(Suppl):E134-40 (Pubitemid 30435751)
2. Shiratori Y, Shiratori Y, Imazeki F, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000;132:517-524 (Pubitemid 30171890)
3. Poynard T, Poynard T, McHutchison J, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002;122:1303-1313 (Pubitemid 34465173)
4. Pol S, Carnot F, Nalpas B, et al. Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 2004;35:107-112
5. Serpaggi J, Carnot F, Nalpas B, et al. Direct and indirect evidence for the reversibility of cirrhosis. Hum Pathol 2006;37:1519-1526 (Pubitemid 44792230)
6. Di Marco V, Almasio PL, Ferraro D, et al. Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial. J Hepatol 2007;47:484-491 (Pubitemid 47336987)
7. Everson GT, Balart L, Lee SS, et al. Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis. Aliment Pharmacol Ther 2008;27:542-551 (Pubitemid 351316789)
8. Zois CD, Baltayiannis GH, Karayiannis P, Tsianos EV. Systematic review: hepatic fibrosis-regression with therapy. Aliment Pharmacol Ther 2008;28:1175-1187
9. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008;149:399-403
10. Bruno S, Stroffolini T, Colombo M, et al.; Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alfa is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007;45:579-587
11. Braks RE, Ganne-Carrie N, Fontaine H, et al. Effect of sustained virological response on long-term clinical outcome in 113 patients with compensated hepatitis C-related cirrhosis treated by interferon alpha and ribavirin. World J Gastroenterol 2007;13:5648-5653 (Pubitemid 350031486)
12. Garcia-Retortillo M, Forns X, Feliu A, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002;35:680-687 (Pubitemid 34183974)
13. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000;32:673-684 (Pubitemid 30180389)
14. Heathcote EJ, Shiffman ML, Cooksley WG, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med 2000;343:1673-1680
15. Abergel A, Hezode C, Leroy V, et al.; French multicenter study group. Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial compared two doses of peginterferon alpha-2b. J Viral Hepat 2006;13:811-820 (Pubitemid 44748285)
16. Helbling B, Jochum W, Stamenic I, et al.; Swiss Association for the Study of the Liver (SASL). HCV-related advanced fibrosis/ cirrhosis: randomized controlled trial of pegylated interferon a-2a and ribavirin. J Viral Hepat 2006;13:762-769
17. Syed E, Rahbin N, Weiland O, et al. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C virus infection in patients with Child-Pugh Class A liver cirrhosis. Scand J Gastroenterol 2008;43:1378-1386 • This manuscript will be of interest to readers.
18. Roffi L, Colloredo G, Pioltelli P, et al.; Gruppo Epatologico Lombardo. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther 2008;13:663-673
19. Marrache Y, Consigny MP, Ripault D, et al. Safety and efficacy of peginterferon plus ribavirin in patients with chronic hepatitis C and bridging fibrosis or cirrhosis. J Viral Hepat 2005;12:421-428 (Pubitemid 40961483)
20. Floreani A, Baldo V, Rizzotto ER, et al. Pegylated interferon alpha-2b plus ribavirin for naive patients with HCV-related cirrhosis. J Clin Gastroenterol 2008;42:734-737
21. Crippin JS, McCashland T, Terrault N, et al. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355 (Pubitemid 34467369)
22. Thomas RM, Brems JJ, Guzman-Hartman G, et al. Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation. Liver Transpl 2003;9:905-915 (Pubitemid 37098838)
23. Forns X, García-Retortillo M, Serrano T, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol 2003;39:389-396 (Pubitemid 37070256)
24. Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255-262 (Pubitemid 41061075)
25. Iacobellis A, Siciliano M, Perri F, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol 2007;46:206-212 (Pubitemid 44959155)
26. Tekin F, Gunsar F, Karasu Z, et al. Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in HCV-related decompensated cirrhotics. Aliment Pharmacol Ther 2008;27:1081-1085 (Pubitemid 351614890)
27. Annicchiarico BE, Siciliano M, Avolio AW, et al. Treatment of chronic hepatitis C virus infection with pegylated interferon and ribavirin in cirrhotic patients awaiting liver transplantation. Transplant Proc 2008;40:1918-1920
28. Iacobellis A, Siciliano M, Annicchiarico BE, et al. Sustained virologic responses following standard antiviral therapy in decompensated HCV-infected cirrhotic patients. Aliment Pharmacol Ther 2009 [Epub 17 Apr 2009]
29. McHutchinson JG, Manns MP, Longo DL. Definition and management of anaemia in patients infected with hepatitis C virus. Liver Int 2006;26:389-398
30. Sulkowski MS, Wasserman R, Brooks L, et al. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat 2004;11:243-250 (Pubitemid 38658449)
31. De Franceschi L, Fattovich G, Turrini F. Haemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000;31:997-1004 (Pubitemid 30169949)
32. Dar Santos AE, Partovi N, Ford JA, Yoshida EM. Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. Ann Pharmacother 2007;41:268-275 (Pubitemid 46340057)
33. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004;71:S17-21
34. Sulkowski MS. Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis 2003;37(Suppl 4):315-322
35. Wasserman R, Brau N, Hassanein T, et al. Once weekly epoietin alfa increases hemoglobin and decreases RBV discontinuation among HCV patients who develop anemia on RBV/IFN therapy. Hepatology 2000;32(Suppl):368A
36. Younossi ZM, Ong JP, Collantes R, et al. Darbepoetin alfa for ribavirin-induced anemia in patients with chronic hepatitis C treated with pegylated interferon and ribavirin. Gastroenterology 2004;126(Suppl 2):83B
37. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982
38. Koirala J, Gandotra SD, Rao S, et al. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy. J Viral Hepatol 2007;14:782-787 (Pubitemid 47561582)
39. Antonini MG, Babudieri S, Maida I, et al. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin. Infection 2008;36:250-255
40. Cooper CL, Al-Bedwawi S, Lee C, Garber G. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 2006;42:1674-1678 (Pubitemid 43839429)
41. Forns X, Afdhal NH, McHutchison JG. Review article: pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection. Aliment Pharmacol Ther 2007;26(Suppl 1):29-39 (Pubitemid 47631868)
42. Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000;95:2936-2939
43. Giannini EG. Review article: thrombocytopenia in chronic liver disease and pharmacologic treatment options. Aliment Pharmacol Ther 2003;23:1055-1065
44. McCormick PA, Murphy KM. Splenomegaly, hypersplenism and coagulation abnormalities in liver disease. Baillieres Best Pract Res Clin Gastroenterol 2000;14:1009-1031 (Pubitemid 32094271)
45. Weksler BB. Review article: the pathophysiology of thrombocytopenia in hepatitis C virus infection and chronic liver disease. Aliment Pharmacol Ther 2007;26(Suppl 1):13-19 (Pubitemid 47631869)
46. Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001;113:590-595 (Pubitemid 32524375)
47. Rios R, Sangros E, Herrero I, et al. The role of thrombopoietin in the thrombocytopenia of patients with liver cirrhosis. Am J Gastroenterol 2005;100:1311-1316 (Pubitemid 40904354)
48. Bordin G, Ballarè M, Zigrossi P, et al. A laboratory and thrombokinetic study of HCV-associated thrombocytopenia: a direct role of HCV in bone marrow exhaustion? Clin Exp Rheumatol 1995;13(Suppl 13):39-43
49. Wang R, Furihata K, McFarland JG, et al. An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system. J Clin Invest 1992;90:2038-2043
50. Nagamine T, Ohtuka T, Takehara K, et al. Thrombocytopenia associated with hepatitis C viral infection. J Hepatol 1996;24:135-140 (Pubitemid 26059114)
51. Bauduer F, Marty F, Larrouy M, Ducout L. Immunologic thrombocytopenic purpura as presenting symptom of hepatitis C infection. Am J Hematol 1998;57:338-340 (Pubitemid 28158423)
52. McHutchison JG, Geoffrey Dusheiko, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 2007;357:2227-2236 (Pubitemid 350190753)
53. Colombo M, Kuo G, Choo QL, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet 1989;2:1006-1008 (Pubitemid 19257916)
54. Berenguer M, Prieto M, Rayon JM, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000;32:852-858 (Pubitemid 30744287)
55. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002;122:889-896 (Pubitemid 34267271)
56. Wiesner RH, Sorrell M, Villamil F. The international liver transplantation society expert. Report of the first international liver transplantation society expert panel consensus Conference on liver transplantation and hepatitis C. Liver Transpl 2003;9:S1-9
57. Fink S, Gaglio PJ. Hepatitis C in liver transplant patients. Curr Hepat Rep 2008;7:81-87
58. Mallet V, Gilgenkrantz H, Serpaggi J, et al. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatits C. Ann Intern Med 2008;149:399-403
59. Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alfa 2b. Hepatology 1993;18:1300-1305 (Pubitemid 23348413)
60. Shiffmann M, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997;26:780-785 (Pubitemid 27392374)
61. Ziol M, Van Nhieu JT, Roudot-Thoraval F, et al. A histopathological study of the effects of 6-month versus 12-month interferon alpha-2b therapy in chronic hepatitis C. J Hepatol 1996;25:833-841 (Pubitemid 27008114)
62. Bonis PA, Ioannidis JP, Cappelleri JC, et al. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology 1997;26:1035-1044
63. Aghemo A, Rumi MG, Soffredini R, et al. Impaired response to interferon-α2b plus ribavirin in cirrhotic patients with genotype 3a hepatitis C virus infection. Antivir Ther 2006;11:797-802 (Pubitemid 44497175)
64. Carrión JA, Martínez-Bauer E, Crespo G, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 2009;50:719-728